Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents

Pio Lopez, Lulu Bravo, Erik Buntinx, Charissa Borja-Tabora, Hector Velasquez, Edith Johana Rodriguez, Camilo A. Rodriquez, Josefina Carlos, May Emmeline B. Montellano, Edison R. Alberto, Milagros Salvani-Bautista, Yung Huang, Branda Hu, Ping Li, Htay Htay Han, Carmen Baccarini, Igor Smolenov
doi: https://doi.org/10.1101/2023.02.22.23286317

Article Information

doi 
https://doi.org/10.1101/2023.02.22.23286317
History 
  • February 26, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Pio Lopez1,
  2. Lulu Bravo2,
  3. Erik Buntinx3,
  4. Charissa Borja-Tabora4,
  5. Hector Velasquez5,
  6. Edith Johana Rodriguez5,
  7. Camilo A. Rodriquez6,
  8. Josefina Carlos7,
  9. May Emmeline B. Montellano8,
  10. Edison R. Alberto9,
  11. Milagros Salvani-Bautista7,
  12. Yung Huang10,
  13. Branda Hu10,
  14. Ping Li10,
  15. Htay Htay Han10,
  16. Carmen Baccarini10 and
  17. Igor Smolenov10,*
  1. 1Centro de Estudios en Infectología Pediátrica, Universidad Del Valle Clínica Imbanaco, Cali, Colombia
  2. 2University of the Philippines Manila, Ermita, Manila, The Philippines
  3. 3Anima Research Center, Alken, Belgium
  4. 4Asian Hospital and Medical Center, Alabang, Muntinlupa, Philippines
  5. 5Center of Attention in Medical Research (CAIMED), Bogotá, Colombia
  6. 6Policlínico Social del Norte, Bogotá, Colombia
  7. 7University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, the Philippines
  8. 8Far Eastern University Hospital - Nicanor Reyes Medical Foundation, Quezon City, the Philippines
  9. 9Tropical Disease Foundation-HIMC, Cavite City, the Philippines
  10. 10Clover Biopharmaceuticals, Boston, MA, USA
  1. ↵*Corresponding author
    Igor Smolenov, M.D., 200 State Street, Suite 1105, Boston, MA 02109, United States, Tel. +1 206 399-0270; smolenov{at}gmail.com
Back to top
Posted February 26, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
Pio Lopez, Lulu Bravo, Erik Buntinx, Charissa Borja-Tabora, Hector Velasquez, Edith Johana Rodriguez, Camilo A. Rodriquez, Josefina Carlos, May Emmeline B. Montellano, Edison R. Alberto, Milagros Salvani-Bautista, Yung Huang, Branda Hu, Ping Li, Htay Htay Han, Carmen Baccarini, Igor Smolenov
medRxiv 2023.02.22.23286317; doi: https://doi.org/10.1101/2023.02.22.23286317
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area